Sterling Investment Management LLC Sells 227 Shares of Johnson & Johnson (NYSE:JNJ)

Sterling Investment Management LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 13,421 shares of the company’s stock after selling 227 shares during the period. Johnson & Johnson makes up about 1.5% of Sterling Investment Management LLC’s investment portfolio, making the stock its 25th biggest position. Sterling Investment Management LLC’s holdings in Johnson & Johnson were worth $1,941,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in JNJ. State Street Corp grew its holdings in shares of Johnson & Johnson by 0.9% in the 3rd quarter. State Street Corp now owns 134,245,811 shares of the company’s stock worth $21,755,874,000 after purchasing an additional 1,154,088 shares during the last quarter. Geode Capital Management LLC grew its stake in Johnson & Johnson by 1.8% during the third quarter. Geode Capital Management LLC now owns 56,106,884 shares of the company’s stock worth $9,064,149,000 after buying an additional 1,004,763 shares during the last quarter. FMR LLC increased its holdings in shares of Johnson & Johnson by 7.4% during the third quarter. FMR LLC now owns 18,316,920 shares of the company’s stock worth $2,968,440,000 after buying an additional 1,265,748 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Johnson & Johnson by 0.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company’s stock valued at $2,858,543,000 after acquiring an additional 102,502 shares during the last quarter. Finally, Franklin Resources Inc. grew its position in Johnson & Johnson by 11.4% during the 3rd quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock worth $2,721,355,000 after acquiring an additional 1,729,281 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In related news, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Wolfe Research assumed coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective on the stock. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Thursday. Guggenheim increased their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Finally, Bank of America dropped their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $170.06.

Johnson & Johnson Stock Up 0.1 %

Shares of NYSE:JNJ opened at $146.76 on Friday. The company has a 50 day moving average price of $147.99 and a two-hundred day moving average price of $155.98. The company has a market capitalization of $353.34 billion, a PE ratio of 22.07, a PEG ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22,438,500 billion. During the same quarter last year, the business posted $2.29 EPS. The firm’s revenue was up 5.3% compared to the same quarter last year. Analysts forecast that Johnson & Johnson will post 10.56 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.38%. Johnson & Johnson’s payout ratio is 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.